CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with Congenital Adrenal Hyperplasia (CAH). There is provided a use of a composition comprising a CRF1 receptor antagonist, wherein the CRF1 receptor antagonist is selected from the group consisting of 2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine (NBI-77860), 5-[7-(dipropylamino)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-3-yl]-N,N,4-trimethylpyridin-2-amine (NBI-30775), and 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-(2-propyn-1-yl)-2-thiazolamine (SSR-125543), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating CAH.